European Commission grants Vico Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia
News provided by
Share this article
a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the European Commission (EC) has granted orphan drug designation for VO659, Vico s investigational antisense oligonucleotide therapy for the treatment of Spinocerebellar Ataxia (SCA). The orphan designation was based on a positive opinion from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP). Vico previously received orphan drug designation for VO659 in Huntington Disease. Spinocerebellar Ataxias
IME Medical Electrospinning and STENTiT enter into development cooperation on resorbable endovascular support grafts to regenerate vascular tissue
News provided by
Share this article
Share this article
WAALRE, Netherlands, Feb. 10, 2021 /PRNewswire/ IME Medical Electrospinning, a global leader in electrospun medical devices, today announced that it has entered into a collaboration with Dutch medical device company STENTiT, to join forces in the further development and production of regenerative
). These resorbable fibrous implants hold the promise to rebuild a new blood vessel inside the existing artery, by exploiting the natural healing response of the body.
IME s technological solutions enable the manufacturing of innovative devices like STENTiT s endovascular support grafts, which are aimed to mimic the natural human extracellular matrix for implants in the human body in nanometer and micrometer format. Human cells rebuild these matrices leading to new body tissue. This
LG Chem is the first to receive WHO prequalification for the sIPV vaccine
LG Chem signed an $80 million contract with UNICEF to supply polio vaccine starting early 2021
BILTHOVEN, the Netherlands, Jan. 21, 2021 /PRNewswire/
Intravacc, a world leader in translational research and development of vaccines, today announces the WHO prequalification for the Sabin-IPV (sIPV) vaccine Eupolio™, developed by Intravacc and out-licensed to South Korean LG Chem in 2014. The vaccine was developed by Intravacc for technology transfer to manufacturers in low- and middle-income countries in the context of the global polio eradication initiative.
Eupolio™ received the prequalification status from the World Health Organization (WHO) by the end of December. LG Chem signed a contract with UNICEF to supply $80 million worth of polio vaccine Eupolio™ from 2021 to 2022. The company will supply the vaccine to 70 countries in the Middle East, Africa and Southeast Asia starting in January 202
Share this article
Share this article
- Potentially the first preventive vaccine for coxsackievirus B, a risk factor associated with type 1 diabetes and celiac disease
- First dosing of PRV-101 in the PROVENT Phase I clinical trial started in January 2021
BILTHOVEN, Netherlands, Jan. 19, 2021 /PRNewswire/
Intravacc, a world leader in translational research and development of vaccines, today announced that a candidate polyvalent inactivated coxsackievirus B (CVB) vaccine it developed and manufactured for Provention Bio in less than 36 months, has entered into a first in human Phase I clinical study called PROVENT (PROtocol for coxsackievirus Vaccine in healthy volunteers) .
Provention Bio is clinical stage biopharmaceutical company, that selected Intravacc in 2018 to lead product development and manufacturing of clinical study material for Provention s vaccine candidate (PRV-101). This CVB vaccine candidate is developed for the intended prevention of acute CVB infection and
Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms
- First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2
- Evaluation of Cristal s CliCr® and Intravacc s OMV technology
News provided by
Share this article
, a world leader in translational research and development of vaccines, and Cristal Therapeutics, a technology leader in enabling safer and more effective therapeutics, today announced a strategic collaboration to develop novel vaccine programs against human diseases with the initial candidate targeting COVID-19.
(PRNewsfoto/Intravacc B.V.)
Under the terms of the agreement, Cristal Therapeutics and Intravacc will collaborate with an initial focus on generating a CriVac